tirzepatide news 2025 New clinical trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss Tirzepatide Reduces Food Intake and

In this blog post, well explore the importance of self-testing and delve into the benefits of monitoring blood pressure and heart rate, temperature, pulse oximetry, and blood glucose levels from the comfort of your own space

They have been quick to respond and timely with deliveries

For now, both drugs are positioned as potentially transformative next-generation treatments that could offer advantages over existing single-target GLP-1 agonists

If you are four weeks in with no weight loss , do not panic immediately

(2015) "MOTS-c promotes metabolic homeostasis." Published in Cell Metabolism

The peptide's predictable dose-response and extended stability in culture media have made it a preferred growth factor supplement in CHO cell culture, stem cell expansion, and primary cell isolation protocols across hundreds of published studies